Final posted 2025 04 11 508

Final Agenda
Dr. Keipp Talbot (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:15 Mpox Vaccine
Introduction
Presentation on immunogenicity and safety of JYNNEOS in 12-17 year olds
EtR for JYNNEOS in outbreaks and due to the 2022 global outbreakDr. Faisal Minhaj (CDC/NCEZID)
Dr. Buddy Creech (Vanderbilt University)
Dr. Faisal Minhaj (CDC/NCEZID)
9:55 Lyme Disease Vaccine Dr. Grace Marx (CDC/NCEZID)
10:00 Influenza Vaccines
I
ntroduction
Influenza vaccine effectiveness update
FluMist self/caregiver administrationDr. Jamie Loehr (ACIP, WG Chair)
Dr. Aaron Frutos (CDC/NCIRD)
Dr. Sophie Zhu (California DPH and CDC/PHIC), Dr.
Joshua Quint (California DPH)
Dr. Allyn Bandell (AstraZeneca)
11:15 Break
11:30 COVID-19 Vaccines
Introduction
Moderna mRNA-1283 COVID-19 vaccine
Epidemiology and risk factors for COVID-19 hospitalizations
Vaccine effectiveness update
Workgroup considerations for use of 2025-2026 COVID-19 vaccinesDr. Robert Schechter (ACIP, WG Chair)
Dr. Bishoy Rizkalla (Moderna)
Dr. Fiona Havers (CDC/NCIRD)
Dr. Ruth Link-Gelles (CDC/NCIRD)
Dr.  Lakshmi Panagiotakopoulos (CDC/NCIRD)
1:30 Pneumococcal Vaccines
Workgroup Next Steps and Proposed Work Plan Dr. Miwako Kobayashi (CDC/NCIRD)
1:45 B reak
2:00 Human Papillomavirus (HPV) Vaccines
Introduction
Update on literature related to reduced number of doses for HPV vaccination
KEN SHE trial
HPV vaccination coverage
Modeling of reduced number of doses for HPV vaccination
Modified EtR: wording of the age for routine HPV vaccination
Workgroup next steps and considerationsDr. Oliver Brooks (ACIP, WG Chair)
Dr. Carla DeSisto (CDC/NCIRD)
Dr. Ruanne Barnabas (Harvard University)
Ms. Cassandra Pingali (CDC/NCIRD)
Dr. Jane Kim (Harvard University)
Dr. Ruth Stefanos (CDC/NCIRD)
Dr. Lauri Markowitz (CDC/NCIRD)
4:00 Cytomegalovirus (CMV) Vaccines
Introduction
CMV and cCMV epidemiology and disease burden
CMV vaccine safety and immunogenicity data
Initial workgroup considerations for CMV vaccine policyDr. Denise Jamieson (ACIP, WG Chair)
Dr. Tatiana Lanzieri  (CDC/NCIRD)
Dr. Robert Paris (Moderna)
Dr. Tatiana Lanzieri  (CDC/NCIRD)
Dr. David Sugerman (CDC/NCIRD) 5:00 U.S. Measles Update
5:30 AdjournMEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
C
enters for Disease Control and Prevention
Atlanta, Georgia 30329
Tuesday, April 15, 2025
8:00 Welcome & Introductions
Final Agenda
Dr. Keipp Talbot (ACIP Chair)
8:15 Meningococcal Vaccines
Introduction
GSK pentavalent vaccine: update of EtR and workgroup considerations
Updates to Meningococcal vaccines VFC resolution
Introduction to MenQuadfi label change for infants
MenQuadfi in infants: safety and immunogenicity
Workgroup considerations regarding MenQuadfi in infantsDr. Jamie Loehr (ACIP, WG Chair)
Dr. Sarah Schillie (CDC/NCIRD)
Dr. Jeanne Santoli (CDC/NCIRD)
Dr. Sarah Schillie (CDC/NCIRD)
Dr. Rachel Dawson (Sanofi)
Dr. Sarah Schillie (CDC/NCIRD)
9:30 Break
9:45 Respiratory Syncytial Virus (RSV) Vaccines - Adults
Introduction
Manufacturer Presentation: mRNA-1345 (Moderna) Immunogencity in Adults
18-59 at Increased Risk; 24-Month Re-Vaccination
Manufacturer Presentation: Arexvy (GSK) 36-Month Re-Vaccination
Economic Analysis of Adult RSV Vaccination, including benefits and risk
discussion
Comparison of Economic Analyses of Adult RSV Vaccination
Evidence to Recommendations
Clinical ConsiderationsDr. Albert Shaw (ACIP, WG Chair)
Dr. Frances Priddy (Moderna)
Dr. Susan Gerber (GSK)
Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
Dr. Diya Surie (CDC/NCIRD), Dr. Michael Melgar
(CDC/NCIRD)
Dr. Diya Surie (CDC/NCIRD)
12:15 Break
12:30 Chikungunya Vaccines
In
troduction
EtR for use of virus-like particle chikungunya vaccine among adolescent and
adult travelers
EtR for use of virus-like particle chikungunya vaccine among laboratory workers
Surveillance for adverse events following use of live attenuated chikungunya
vaccine and its use among travelers
Clinical guidance for use of virus-like particle chikungunya vaccine among
pregnant and breastfeeding womenDr. Edwin Asturias (ACIP/WG Chair)
Dr. Susan Hills (CDC/NCEZID)
Dr. Erin Staples (CDC/NCEZID)
Dr. Susan Hills (CDC/NCEZID),
Dr. Erin Staples (CDC/NCEZID)
Dr. Susan Hills (CDC/NCEZID), Dr. Dana Meaney-
Delman (CDC/NCBDDD)
3:00 Break
3:10 Public Comment
3:40 VOTES
Meningococcal Vaccines
Meningococcal Vaccines VFC
RSV Adult
Chikungunya VaccinesDr. Sarah Schillie (CDC/NCIRD)
Dr. Jeanne Santoli (CDC/NCIRD)
Dr. Michael Melgar (CDC/NCIRD)
Dr. Susan Hills (CDC/NCEZID)
4:10 Respiratory Syncytial Virus (RSV) Immunizations- Maternal/Pediatric
Introduction
EtR: Clesrovimab
Clinical considerationsDr. Helen Chu (ACIP, WG Chair)
Ms. Danielle Moulia (CDC/NCIRD)
Dr. Jefferson Jones (CDC/NCIRD)
5
:10AdjournWednesday, April 16, 2025
8:
00
Welcome & Introductions
Final Agenda
Acronyms
cCMV Congenital cytomegalovirus
CDC Centers for Disease Control and Prevention
CMV Cytomegalovirus
COVID-19 Coronavirus disease 2019
DPH Department of Public Health
EtR Evidence to Recommendations Framework
HPV Human papillomavirus
NCBDDD National Center on Birth Defects and Developmental Disabilities
NCIRD National Center for Immunization & Respiratory Diseases
NCEZID National Center for Emerging and Zoonotic Diseases
PHIC Public Health Infrastructure Center
RSV Respiratory Syncytial Virus
WG Work Group
VFC Vaccines for Children

Summary: Final Agenda Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC) 8:15 Mpox Vaccine  Introduction Presentation on immunogenicity and safety of JYNNEOS in 12-17 year olds EtR for JYNNEOS in outbreaks and due to the 2022 global outbreakDr. Faisal Minhaj (CDC/NCEZID) Dr. Buddy Creech (Vanderbilt University) Dr. Faisal Minhaj (CDC/NCEZID) 9:55 Lyme Disease Vaccine Dr. Grace Marx (CDC/NCEZID) 10:00 Influenza Vaccines  I ntroduction Influenza vaccine effectiveness update…